Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DuoGenic StemCellsROCO:7607 -0.76%25 Gross Margin % is 74.21% as of Dec. 2025, which is 118% above its 10-year median of 34.04. GuruFocus rates ROCO:7607 with a GF Score™ of 25/100 and a GF Value™ of NT$51.22 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 733 Biotechnology companies, DuoGenic StemCells ranks better than 67.8% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
DuoGenic StemCells had a gross margin of 74.21% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
DuoGenic StemCells Gross Margin % Related Terms
DuoGenic StemCells Gross Margin % Historical Data
* Premium members only.
The historical data trend for DuoGenic StemCells's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7607 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, DuoGenic StemCells's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DuoGenic StemCells Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, DuoGenic StemCells's Gross Margin % distribution charts can be found below:
* The bar in red indicates where DuoGenic StemCells's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
DuoGenic StemCells (ROCO:7607) has a Gross Margin % of 74.21% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on DuoGenic StemCells and its competitors. This is 118% above median its historical median of 34.04. According to the industry distribution chart, DuoGenic StemCells ranks #236 out of 733 companies in the Biotechnology industry, placing it in the top 32.2%.
Is DuoGenic StemCells' Gross Margin % too high?
DuoGenic StemCells' current Gross Margin % of 74.21% is 118% above median its 10-year median of 34.04. The Biotechnology industry median Gross Margin % is 60.91. DuoGenic StemCells' value of 74.21% is 21.8% above this industry median. Based on the distribution chart, DuoGenic StemCells ranks #236 out of 733 companies in the Biotechnology industry, which is above the industry midpoint. Overall, DuoGenic StemCells has a GF Score™ of 25/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DuoGenic StemCells' Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, DuoGenic StemCells ranks #236 out of 733 companies for Gross Margin %. This puts DuoGenic StemCells in the upper half of its industry. The industry median Gross Margin % is 60.91. DuoGenic StemCells' value of 74.21% is 21.8% above this benchmark. While the company's 10-year median is 34.04 vs. the industry median of 60.91, DuoGenic StemCells has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 733 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DuoGenic StemCells's current Gross Margin % of 74.21% is 21.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on DuoGenic StemCells and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DuoGenic StemCells's current Gross Margin % is 74.21%, which is 118% above median its own 10-year median of 34.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DuoGenic StemCells stock overvalued right now?
Based on GuruFocus' analysis, DuoGenic StemCells (ROCO:7607) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$51.22, compared to a current price of NT$13.00 — trading 74.6% below its estimated fair value. The current Gross Margin % is 74.21%, which is 118% above median its 10-year median of 34.04 and 21.8% above the Biotechnology industry median of 60.91. DuoGenic StemCells' overall GF Score™ is 25/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For DuoGenic StemCells (ROCO:7607), the current Gross Margin % is 74.21% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DuoGenic StemCells (ROCO:7607) Overvalued in 2026?
Based on GuruFocus' analysis, DuoGenic StemCells stock appears to be undervalued.
The current stock price of NT$13.00 is trading 74.6% below its estimated GF Value™ of NT$51.22.
GuruFocus considers DuoGenic StemCells to be Significantly Undervalued.
Key valuation signals for ROCO:7607:
Gross Margin %: 74.21% (118% above median its 10-year median of 34.04)
GF Value™: NT$51.22 vs. price of NT$13.00 (74.6% below fair value)
Industry Position: 21.8% above the Biotechnology median (#236 of 733)
No single metric tells the full story. See the ROCO:7607 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DuoGenic StemCells Corp is a company having a team of passionate researchers focused on stem cell cultivation. Their products are intended for research use and can be upgraded for clinical applications. It also develops blood cell therapy programs, using the isolation and purification of blood mononuclear cells to remove granule cells that promote inflammation, and conducts clinical trials on various degenerative diseases to provide a convenient and simple new option for cell therapy.
25GF Score
Get the complete analysis for ROCO:7607
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7607 has been successfully added to your 
